EISAI INNOVATION, INC.
Is a strategic investment
organization aspiring to identify
synergies between the scientific
community and the Eisai network
of companies. Our investment
work aims to...
Help create a world free from fear and pain of disease
Make predictions about future diseases and consider sustainable development goals for healthcare.
Acquire innovative assets and businesses
Lead Eisai into the top 10 health care companies by collaborating with biotech and digital health companies and through M&A.
Establish full-scale global CVI (Corporate Venture Investment) capability
Enable Eisai to take a leadership position in supporting academic-established startups.
Keep up with the latest research
Cutting-edge technologies, drug modalities and digital healthcare solutions all enable Eisai to create a near- and long-term term strategy.
Foster top talent
Translate newly obtained knowledge into action.
About
Goals
Strategic investment to create
synergy with Eisai’s business
Regions
Global investment (US,
Europe, Japan, China, Emerging markets including Africa)
Period
~10 years for exit
Target
Neurology & Oncology and their
digital solutions, Diagnostics
Size
~$5 M USD/investment
Investments
Leadership
YOSHIHARU MIZUI
President of Eisai Innovation, Inc.
Yoshiharu Mizui founded Eisai Innovation, Inc. in 2019. Prior to that he was a global head of the BD/Strategy Department in Oncology Business Group at Eisai from 2016-2019. He was also a founding member of H3 Biomedicine and led the oncology program from 2011-2016. He has more than 20 years of experience as a discovery research biologist. He received his Ph.D. from Kyushu University.
KOU QIN, PH.D.
Managing Director of Investment, Cambridge office
Kou Qin joined Eisai Innovation, Inc. in 2021. Previously at MSA Capital, he was in charge of healthcare strategy and investment globally. Prior to that, he ran the corporate incubation program at BGI. He started Skinome, a skin disease diagnosis company, invested by Y Combinator (YC) fellowship. He received his Ph.D. in neuroscience from the Medical College of Georgia, and Master of Science degree from the public health school of Harvard University.
PAUL WU, PH.D.
Investment Principal, San Francisco office
Paul Wu joined Eisai Innovation, Inc in 2022. His professional background includes venture capital, strategic business development, and entrepreneurship. Most recently, he led early-stage investments at Grey Sky Venture Partners focusing on health, biotechnology, and digital companies. He earned his MBA from MIT Sloan and his Ph.D. in Biomedical Engineering from Northwestern University.
Please include your name, organization, global location and a short message regarding your interest. In the subject line, please indicate if this is regarding COLLABORATIONS, INVESTMENTS or GENERAL INFO.
About Eisai: Eisai is a leading global research and development-based pharmaceutical company headquartered in Japan,
with approximately 10,000 employees worldwide. We define our corporate mission as “giving first thought to patients and
their families and to increasing the benefits health care provides,” which we call our human health care (hhc) philosophy.
We strive to realize our hhc philosophy by delivering innovative products in therapeutic areas with high unmet medical
needs, including Oncology and Neurology. In the spirit of hhc, we take that commitment even further by applying our
scientific expertise, clinical capabilities and patient insights to discover and develop innovative solutions that help address
society's toughest unmet needs, including neglected tropical diseases and the Sustainable Development Goals.
For more information about Eisai, please visit www.eisai.com (for global), us.eisai.com (for U.S.) or www.eisai.eu (for Europe,
Middle East, Africa).